Infinium Pharmachem Past Earnings Performance
Past criteria checks 3/6
Infinium Pharmachem has been growing earnings at an average annual rate of 42.7%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 9.6% per year. Infinium Pharmachem's return on equity is 18.3%, and it has net margins of 10.6%.
Key information
42.7%
Earnings growth rate
41.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -9.6% |
| Return on equity | 18.3% |
| Net Margin | 10.6% |
| Last Earnings Update | 30 Sep 2023 |
Revenue & Expenses Breakdown
How Infinium Pharmachem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 964 | 102 | 56 | 0 |
| 30 Jun 23 | 1,053 | 98 | 57 | 0 |
| 31 Mar 23 | 1,142 | 95 | 58 | 0 |
| 31 Mar 22 | 991 | 61 | 39 | 0 |
| 31 Mar 21 | 548 | 27 | 24 | 0 |
| 31 Mar 20 | 364 | 10 | 21 | 0 |
| 31 Mar 19 | 181 | 4 | 13 | 0 |
Quality Earnings: INFINIUM has a high level of non-cash earnings.
Growing Profit Margin: INFINIUM's current net profit margins (10.6%) are higher than last year (7.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INFINIUM's earnings have grown significantly by 42.7% per year over the past 5 years.
Accelerating Growth: INFINIUM's earnings growth over the past year (30.6%) is below its 5-year average (42.7% per year).
Earnings vs Industry: INFINIUM earnings growth over the past year (30.6%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: INFINIUM's Return on Equity (18.3%) is considered low.